Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Angelalign Technology Inc (AGLFF) fair value: what the stock is really worth
We calculate from audited financials what Angelalign Technology Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
AT
Broad data
Sep 13, 2026
Broad data
Sep 13, 2026
Angelalign Technology Inc
AGLFF · USOvervalued / MonitorQuality growthQuality is not strong enough to offset the price risk.
!Fair value $8.02 · Overvalued (−35%)
✓Quality 72/100
!Weak Growth (revenue 5y −14.6 %/yr)
!Thin margins · 7.7% net margin (TTM)
✓Low debt · generates free cash flow
·0.50% dividend yield
!Narrow moat 43/100
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
30‑month range $6.44 – $12.28 · fair‑value band $5.62 – $10.44 · the $12.28 price screens above the $8.02 fair value. Dashed = 300-day average. As of Sep 13, 2026.
Company profile
Angelalign Technology Inc., an investment holding company, researches and designs, manufactures, sells, and markets clear aligner treatment solutions in the People's Republic of China and internationally.
Show more
Angelalign Technology Inc., an investment holding company, researches and designs, manufactures, sells, and markets clear aligner treatment solutions in the People's Republic of China and internationally. The company's products include Angel Aligner Pro and Angel Aligner Select, a custom made removable clear orthodontic aligners that move the patient's teeth into the proper position over time; Angel Aligner KiD, a early orthodontic solution from prevention to treatment; and Angel Aligner Retainer. It also provides orthodontics and cosmetic dentistry services, and other dental services through its dental clinics. In addition, it sells intraoral scanners, brackets, and other products to hospitals, dental clinics and distributors; and engages in investing activities. Angelalign Technology Inc. was founded in 2003 and is headquartered in Shanghai, China. Angelalign Technology Inc. is a subsidiary of CareCapital Orthotech Limited.
Stock analysis
Angelalign Technology Inc (AGLFF) currently trades at $12.28, while our model-based Fair Value estimate is $8.02, implying the stock looks roughly 53.1% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $5.34 per share, and 0 of the 24 models we run sit above the $12.28 price.
Bear case: the Asset-Based group reads lowest at $1.96, and 24 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: $5.62 (bear) to $10.44 (bull), the price of $12.28 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 72/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Angelalign Technology Inc reported revenue of $370M in FY2025 versus $200M in FY2021, a compound +16.7%/yr. Reported net income was $28.4M in FY2025, compounding −10.8%/yr from FY2021.
Key figures
Market cap $2.1B · P/E ratio 72.2 · P/S ratio 5.55 · EPS (TTM) $0.1700 · Dividend yield 0.5% · Net margin 7.7% · Return on equity 5.4% · Return on assets (EBIT) 2.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades near its 52-week high and 84% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −35%, AGLFF screens cheaper than that median.
Fair Value models
Bear $5.62
Fair Value $8.02
Bull $10.44
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then ($0.0760 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$4.35
$6.60
$12.11
75
Growth DCF
$4.20
$6.98
$11.54
74
Residual Income
$2.15
$2.15
$1.98
74
All 24 models by family
DCF Models
FCF DCF
$4.35
$6.60
$12.11
75
Owner Earnings
$2.08
$3.39
$5.74
72
5Y Revenue Exit
$3.09
$4.76
$7.41
69
5Y EBITDA Exit
$3.33
$5.31
$8.26
72
5Y P/E Exit
$3.37
$5.54
$8.19
68
10Y Revenue Exit
$3.44
$5.34
$7.88
64
10Y EBITDA Exit
$3.65
$5.74
$9.21
65
10Y P/E Exit
$3.68
$5.80
$9.15
61
Earnings-Based
Graham-Dodd
$1.13
$7.34
$10.27
61
Lynch FV
$2.13
$3.05
$3.96
59
PEG = 1.0
$2.13
$3.05
$3.96
55
EPV
$1.90
$2.06
$2.19
71
Multiples
P/E Multiple
$2.25
$3.00
$3.74
63
P/S Multiple
$2.12
$2.83
$3.54
58
P/B Multiple
$2.12
$2.83
$3.54
55
EV/EBIT
$2.81
$3.50
$4.19
66
EV/EBITDA
$2.93
$3.66
$4.39
67
EV/Revenue
$2.41
$3.13
$3.85
54
Asset-Based
NCAV (Graham)
$1.46
$1.96
$2.92
54
Growth DCF
Growth DCF
$4.20
$6.98
$11.54
74
Rev-Margin DCF
$3.09
$4.83
$7.36
69
Economic Profit
Residual Income
$2.15
$2.15
$1.98
74
ROIC Compounder
$1.90
$2.06
$2.19
70
Growth Earnings
Growth-Adj P/E
$2.81
$4.01
$5.22
65
Notify me when AGLFF reaches fair value
Put AGLFF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
72/100
Of which business quality 71 · Market factors (momentum, volatility) 78
Profitability
38
Margins and returns on capital today
Quality Growth
79
Are margins and returns improving?
Cashflow
71
Earnings quality: real cash, not paper profit
Fin. Strength
91
Balance sheet, leverage, solvency risk
Investment
80
Disciplined investing over empire-building
Low Volatility
41
Calm price path (market factor)
Momentum
90
Price trend over the last 3–12 months (market factor)
52W Momentum
100
Distance to the 52-week high (market factor)
Net Issuance
78
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+37.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.6%
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ −23.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−24.0%
Dividend (yield on the price)0.5%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 9%
⚠ Rate on operating basis: 2025 sits 134% above its own trend.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+27.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
AGLFF screens 53% overvalued. Compare with Intuitive Surgical, Inc →
Compare Angelalign Technology Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Context: sector, industry, market
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $369.15 | $350.02 | −5% |
| EssilorLuxottica Société anonyme EL | €146.40 | €161.04 | +10% |
| Medline Inc MDLN | $32.53 | $11.80 | −64% |
| Becton, Dickinson and Company BDX | $177.85 | $100.46 | −44% |
| Alcon Inc ALC | $66.03 | $39.78 | −40% |
| ResMed Inc RMD | A$30.31 | A$33.34 | +10% |
| West Pharmaceutical Services, Inc WST | $346.23 | $137.28 | −60% |
| Sartorius Stedim Biotech S.A DIM | €186.90 | €48.88 | −74% |
| Straumann Holding STMN | CHF 94.10 | CHF 45.50 | −52% |
| Sartorius Aktiengesellschaft SRT3 | €232.90 | €42.05 | −82% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Angelalign Technology Inc (AGLFF) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of $8.02 versus a price of $12.28, about −35% upside (overvalued).
What is the fair value of AGLFF?
Our model-based fair value for Angelalign Technology Inc is $8.02 (as of Sep 13, 2026), built from audited fundamentals. The current price: $12.28.
What is the quality score of AGLFF?
Angelalign Technology Inc has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Angelalign Technology Inc (AGLFF)?
Our model-based price target is the fair value of $8.02 (as of Sep 13, 2026) from 24 valuation models. Cautious scenario $5.62, optimistic scenario $10.44. It is a calculation from audited fundamentals, not an analyst target.
What is the Angelalign Technology Inc stock forecast for 2026?
Our models put fair value at $8.02, about −35% upside versus a price of $12.28 (overvalued). Cautious scenario $5.62, optimistic scenario $10.44. The calculation is refreshed regularly with new filings.
What is the revenue of Angelalign Technology Inc (AGLFF)?
Angelalign Technology Inc reported trailing-twelve-month revenue of about $370M (latest available figure, as of Sep 13, 2026).
Does Angelalign Technology Inc pay a dividend?
Angelalign Technology Inc currently shows a dividend yield of about 0.50% relative to its recent price (as of Sep 13, 2026).
What growth is priced into Angelalign Technology Inc (AGLFF)?
For today's price to be fair in a discounted-cash-flow model, Angelalign Technology Inc would have to grow free cash flow by +27.8 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -14.6 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of AGLFF use?
Our models discount Angelalign Technology Inc at 11.8 %: a base by market capitalisation (small), damped by beta 1.19, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Angelalign Technology Inc that is +27.8 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Angelalign Technology Inc (AGLFF) delivered so far?
Over the past 5 years revenue at Angelalign Technology Inc grew -14.6 % a year. The price currently implies +27.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Angelalign Technology Inc (AGLFF) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Angelalign Technology Inc (+27.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Angelalign Technology Inc (AGLFF)?
The free-cash-flow yield on the price is 2.40 %: that much free cash flow Angelalign Technology Inc produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Angelalign Technology Inc (AGLFF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Angelalign Technology Inc it is $8.02 per share (as of Sep 13, 2026), against a price of $12.28. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Angelalign Technology Inc stock overvalued or undervalued in 2026?
As of Sep 13, 2026, AGLFF trades above its calculated fair value: price $12.28, fair value $8.02, a gap of about −35% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AGLFF?
No. The price is what the market pays today ($12.28); the fair value is what the company's own numbers justify ($8.02). For Angelalign Technology Inc the two are $4.26 per share apart. That gap is exactly why we show both numbers side by side.
How much is Angelalign Technology Inc worth?
The market values Angelalign Technology Inc at about $2.1B (market capitalisation, as of Sep 13, 2026). Per share that is $12.28; our models calculate a fair value of $8.02 per share.
What do the bullish and bearish scenarios say about AGLFF?
Our models span a range for Angelalign Technology Inc: cautious scenario $5.62, base $8.02, optimistic $10.44 per share (as of Sep 13, 2026, price $12.28). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is AGLFF from its 52-week high?
Angelalign Technology Inc trades at $12.28, about 21% below its 52-week high of $10.18 and 84% above the low of $6.68 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of $8.02 is for.
Which stocks are comparable to Angelalign Technology Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Angelalign Technology Inc stock attractive at the current price?
The data as of Sep 13, 2026: price $12.28, calculated fair value $8.02 (−35%), Quality Score 72/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AGLFF calculated?
We run Angelalign Technology Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $8.02, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Angelalign Technology Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Angelalign Technology Inc right now?
A high-quality business (quality 72/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case ($10.44). The favourable scenario is already priced in. A fairly wide model range ($5.62 to $10.44) leaves room in how you read the outcome.
Key figures of Angelalign Technology Inc
How large is the market capitalisation of Angelalign Technology Inc (AGLFF)?
The market capitalisation of Angelalign Technology Inc is $2.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Angelalign Technology Inc (AGLFF)?
The price-to-earnings ratio of Angelalign Technology Inc is 72.2. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Angelalign Technology Inc (AGLFF)?
The price-to-sales ratio of Angelalign Technology Inc is 5.55 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Angelalign Technology Inc (AGLFF)?
Earnings per share at Angelalign Technology Inc are $0.1700 (price ÷ EPS = P/E 72.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Angelalign Technology Inc (AGLFF)?
The dividend yield of Angelalign Technology Inc is 0.5% (payout 36.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Angelalign Technology Inc (AGLFF)?
The net margin of Angelalign Technology Inc is 7.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Angelalign Technology Inc (AGLFF)?
The return on equity (ROE) of Angelalign Technology Inc is 5.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Angelalign Technology Inc (AGLFF)?
On an EBIT basis the return on assets of Angelalign Technology Inc is 2.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Angelalign Technology Inc (AGLFF)?
The operating margin of Angelalign Technology Inc is 9.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Angelalign Technology Inc (AGLFF)?
Revenue at Angelalign Technology Inc is growing +41.6% versus a year earlier (3y avg +26.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Angelalign Technology Inc (AGLFF)?
Earnings per share at Angelalign Technology Inc are growing +60.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Open the live analysis →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.